Brazil Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Brazil · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$233.5 MnPlaceholder estimate
Estimate 2025$259.9 Mn2.9% of the global market
Projected 2034$681.2 Mn 162.1%Adds $421.3 Mn over 9 forecast years
CAGR 2025–203411.3%Faster than 63% of 180 Pharmaceuticals markets here
1 in BrazilSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Brazil Radiopharmaceuticals Market Analysis Executive Summary
Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.
Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).
Brazil Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Brazil Radiopharmaceuticals Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.
Competitive Landscape for Radiopharmaceuticals Market in Brazil
The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Brazil
Radiopharmaceuticals in Brazil: rules, payment and research
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.[2] ClinicalTrials.gov lists 1 study on Radiopharmaceuticals that is recruiting, active or about to start in Brazil.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Isotope
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novartis
7.2 Bayer AG
7.3 Lantheus Holdings
7.4 Curium
7.5 Telix Pharmaceuticals
7.6 GE HealthCare
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The radiopharmaceuticals market can be segmented based on various criteria, including type, isotope and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Radiopharmaceuticals in context
Brazil compared
Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Radiopharmaceuticals market in Brazil?
Placeholder estimate: about $259.9 Mn in 2025, rising to about $681.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Brazil growing?
Placeholder estimate: about 11.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Who regulates Radiopharmaceuticals in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How many clinical trials on Radiopharmaceuticals are running in Brazil?
1 study is recruiting, active or about to start in Brazil, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Brazil 
US
Canada
China
Japan
Germany
France
UK
Italy
Ecuador
Spain
India
Mexico
Saudi Arabia
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
AstraZeneca
Eli Lilly and Company